Immunotherapy Breakthrough: Immune Checkpoint Inhibitors in Cancer Treatment

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering new possibilities for patients with various malignancies. This review examines the molecular mechanisms of immune checkpoints (ICs), particularly the PD-1/PD-L1 and CTLA-4 pathways, and their roles in tumor immune evasion. Major ICIs, including anti-PD-1/PD-L1 and anti-CTLA-4 drugs, are discussed, with emphasis on their effectiveness in treating both solid and hematological cancers. The review also explores combination treatment strategies that aim to improve therapeutic outcomes. Despite considerable progress, challenges such as drug resistance and immune-related adverse events (irAEs) remain. These issues are addressed, alongside an exploration of future directions, including novel ICs such as LAG-3, TIM-3, and TIGIT. The conclusion highlights the significant impact of ICIs on cancer immunotherapy while acknowledging the need for continued research to overcome existing challenges. Future efforts should focus on developing more targeted therapies, optimizing combination treatments, and identifying biomarkers to enhance efficacy and safety, ultimately advancing the field of cancer immunotherapy.